title: The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
abstract: BACKGROUND
  Basal cell carcinomas (BCCs) are the commonest malignancy in the Western world. Locally advanced BCCs (laBCCs) represent tumours that have developed in difficult-to-treat facial sites, aggressively recurrent tumours, large neglected tumours and those in which current treatment options are excluded by clinical or patient-driven criteria. It is estimated laBCCs represent 1% of BCCs.
  
  
  METHODS
  Sonidegib is an oral hedgehog pathway inhibitor with a novel structure. It has recently been licensed for the treatment of laBCC. This article provides a comprehensive review of the literature regarding sonidegib, detailing the pharmacology of the compound, clinical trial data, competitor compounds and a future perspective. Expert commentary: Sonidegib is a novel smoothened (SMO) inhibitor with comparable efficacy to vismodegib, with patient response rates of 44% (sonidegib) and 43% (vismodegib). The adverse effect profile of these two treatments is similar with the main effects being considered to be class effects of SMO inhibitors.
authors.affiliation: a Dermatology Centre, Salford Royal NHS Foundation Trust , University of Manchester, Manchester Academic Health Science Centre , Manchester , UK.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Collier
authors.affiliation: b St John's Institute of Dermatology , St Thomas' Hospital , London , UK.
authors.forename: Faisal R
authors.initials: FR
authors.lastname: Ali
authors.affiliation: a Dermatology Centre, Salford Royal NHS Foundation Trust , University of Manchester, Manchester Academic Health Science Centre , Manchester , UK.
authors.forename: John T
authors.initials: JT
authors.lastname: Lear
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D053823:Hedgehog Proteins / Q000378:metabolism; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000072086:Smoothened Receptor / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D053823:Hedgehog Proteins; D011725:Pyridines; C491023:SMO protein, human; D000072086:Smoothened Receptor; C561435:sonidegib
keywords: Basal cell carcinoma; hedgehog pathway inhibitors; locally advanced basal cell carcinoma; small-molecule inhibitors; smoothened inhibitors; sonidegib